One in eight Americans on GLP-1s

GLP-1 drugs are no longer a niche diabetes treatment or a celebrity weight-loss hack. They are now a mass-market health behavior. By late 2025, KFF found that 12% of U.S. adults said they were currently taking a GLP-1 drug like Ozempic, Wegovy, or Mounjaro. That matters because once a medication reaches that kind of scale, it stops being just a pharma story and starts reshaping food, exercise, retail, and the culture around eating. ### Where does the “one in eight” number come from? It comes from KFF’s national Health Tracking Poll published on November 14, 2025. The striking part is not just the 12% figure. It is the jump. In KFF’s May 2024 poll, 6% of adults said they were currently taking a GLP-1, while 12% said they had ever taken one. Eighteen months later, the “currently taking” number alone reached 12%. Basically, current use doubled fast enough to change consumer markets around it. (kff.org) ### What are these drugs actually doing? GLP-1 drugs blunt appetite, slow stomach emptying, and help people eat less without white-knuckling every meal. That is why they have become such a big deal for obesity and diabetes. But the catch is simple — eating much less can also mean getting too little protein and losing muscle along with fat. That is why the conversation has shifted from “Do these drugs work?” to “How do people live on them well?” (kff.org) ### Why are food companies suddenly talking about them? Because the eating pattern changes are obvious. Smaller appetites mean smaller portions, but users still need enough protein, fiber, and nutrients. That is why brands are rolling out “GLP-1-friendly” meals instead of just generic diet food. In the UK, The Gym Kitchen this week launched a chilled meal range built around smaller portions and nutrient density. (news-medical.net) Bloomberg also reported this week that food companies are pushing protein-rich frozen meals aimed directly at GLP-1 users. ### Why is protein the obsession? Because muscle loss is the part people do not see coming. When calorie intake drops hard, the body does not only burn fat. It can also shed lean mass. Reviews and expert commentaries published in 2025 and 2026 keep landing on the same point — GLP-1 therapy works better when it is paired with resistance training, physical activity, and deliberate nutrition, especially protein intake. (grocerygazette.co.uk) Think of the drug as turning down hunger, not as preserving the engine while the car gets lighter. ### So why does exercise still matter? Because weight loss and health are not the same thing. You can lose pounds and still give up strength, aerobic fitness, and metabolic resilience if movement drops at the same time. A recent perspective on exercise in the GLP-1 era argues that physical activity is still doing jobs the drug does not do well on its own — preserving muscle, supporting function, and helping people maintain results over time. (frontiersin.org) ### What is changing in everyday life? The wellness world is getting reorganized around a smaller-appetite customer. Meal companies are shrinking portion sizes while boosting protein. Beverage companies are pitching products for hydration and nutrient support. Trainers are adjusting advice because people on GLP-1s may feel less energy, recover differently, or under-eat around workouts. This is why the story feels bigger than one drug class — it is becoming a new default consumer profile. (news-medical.net) ### What is the real constraint here? Cost and staying power. KFF’s November 2025 poll also found affordability remains a major problem, with about half of adults saying these drugs are difficult to afford. And many users do not see them as a short sprint. Some expect long-term use, which means the surrounding habits — food, exercise, and routine medical care — matter even more. (bevindustry.com) ### Bottom line? One in eight Americans on GLP-1s is not just a health statistic. It is a market signal and a cultural shift. The drugs are changing how millions of people eat. Now food companies, gyms, and health advice are racing to catch up. (kff.org)